Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This is a phase II intervention to propose a new melanoma chemoprevention agent. The
investigators believe oxidative stress/damage in nevi is a probable indication for melanoma
risk, and propose that reduced melanoma risk in humans can be inferred by protection of nevi
from ultraviolet light (UV)-induced oxidative changes. The investigators will 1) evaluate
whether administration of NAC around the time of UV exposure will reduce melanoma risk in
high-risk patient populations with genetic susceptibility to UV-induced oxidative stress, and
2) examine key genetic variants that will identify which individuals are most likely to
benefit from chemoprotection.